CA2764158A1 - Polynucleotides for multivalent rna interference, compositions and methods of use thereof - Google Patents
Polynucleotides for multivalent rna interference, compositions and methods of use thereof Download PDFInfo
- Publication number
- CA2764158A1 CA2764158A1 CA2764158A CA2764158A CA2764158A1 CA 2764158 A1 CA2764158 A1 CA 2764158A1 CA 2764158 A CA2764158 A CA 2764158A CA 2764158 A CA2764158 A CA 2764158A CA 2764158 A1 CA2764158 A1 CA 2764158A1
- Authority
- CA
- Canada
- Prior art keywords
- region
- polynucleotide
- complementary
- target
- gene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/51—Physical structure in polymeric form, e.g. multimers, concatemers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/52—Physical structure branched
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18301109P | 2009-06-01 | 2009-06-01 | |
| US61/183,011 | 2009-06-01 | ||
| PCT/US2010/036962 WO2010141511A2 (en) | 2009-06-01 | 2010-06-01 | Polynucleotides for multivalent rna interference, compositions and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2764158A1 true CA2764158A1 (en) | 2010-12-09 |
Family
ID=43298453
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2764158A Abandoned CA2764158A1 (en) | 2009-06-01 | 2010-06-01 | Polynucleotides for multivalent rna interference, compositions and methods of use thereof |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US9200276B2 (enExample) |
| EP (1) | EP2438168B1 (enExample) |
| JP (2) | JP5875976B2 (enExample) |
| CN (1) | CN102575252B (enExample) |
| CA (1) | CA2764158A1 (enExample) |
| ES (1) | ES2804764T3 (enExample) |
| WO (1) | WO2010141511A2 (enExample) |
Families Citing this family (149)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2764158A1 (en) | 2009-06-01 | 2010-12-09 | Halo-Bio Rnai Therapeutics, Inc. | Polynucleotides for multivalent rna interference, compositions and methods of use thereof |
| US9115167B2 (en) * | 2011-03-10 | 2015-08-25 | Biomics Biotechnologies Co., Ltd. | Multi-targets interfering RNA molecules and their applications |
| AU2012340159B2 (en) | 2011-11-18 | 2017-09-07 | Alnylam Pharmaceuticals, Inc. | RNAi agents, compositions and methods of use thereof for treating transthyretin (TTR) associated diseases |
| FI3366775T4 (fi) | 2011-11-18 | 2025-11-14 | Alnylam Pharmaceuticals Inc | Modifioituja rnai-agensseja |
| AU2013202315A1 (en) * | 2012-01-04 | 2013-07-18 | Halo-Bio Rnai Therapeutics, Inc. | Nicked polynucleotide complexes for multivalent RNA interference |
| US9663784B2 (en) * | 2012-05-26 | 2017-05-30 | Bonac Corporation | Single-stranded nucleic acid molecule for regulating expression of gene having delivering function |
| US9708607B2 (en) | 2012-08-03 | 2017-07-18 | Alnylam Pharmaceuticals, Inc. | Modified RNAi agents |
| EP3336187A1 (en) | 2012-12-05 | 2018-06-20 | Alnylam Pharmaceuticals, Inc. | Pcsk9 irna compositions and methods of use thereof |
| KR102605775B1 (ko) | 2013-03-14 | 2023-11-29 | 알닐람 파마슈티칼스 인코포레이티드 | 보체 성분 Ｃ5 ｉＲＮＡ 조성물 및 그 이용 방법 |
| BR112015027322A8 (pt) | 2013-05-01 | 2018-01-02 | Isis Pharmaceuticals Inc | Compostos antissenso conjugados e sua utilização |
| MX379208B (es) | 2013-05-22 | 2025-03-10 | Alnylam Pharmaceuticals Inc | Composiciones de arni de serpina1 y sus metodos de uso. |
| EP3828276A1 (en) | 2013-05-22 | 2021-06-02 | Alnylam Pharmaceuticals, Inc. | Tmprss6 irna compositions and methods of use thereof |
| WO2015042564A1 (en) | 2013-09-23 | 2015-03-26 | Alnylam Pharmaceuticals, Inc. | Methods for treating or preventing transthyretin (ttr) associated diseases |
| AU2014362262B2 (en) | 2013-12-12 | 2021-05-13 | Alnylam Pharmaceuticals, Inc. | Complement component iRNA compositions and methods of use thereof |
| CN105899663B (zh) | 2013-12-26 | 2019-07-26 | 学校法人东京医科大学 | 用于基因表达控制的人工模拟miRNA及其用途 |
| CN106068324B (zh) | 2013-12-27 | 2020-12-29 | 株式会社博纳克 | 控制基因表达的人工匹配型miRNA及其用途 |
| WO2015106128A2 (en) | 2014-01-09 | 2015-07-16 | Alnylam Pharmaceuticals, Inc. | MODIFIED RNAi AGENTS |
| EP3105331B1 (en) | 2014-02-11 | 2021-06-23 | Alnylam Pharmaceuticals, Inc. | Ketohexokinase (khk) irna compositions and methods of use thereof |
| WO2015134528A1 (en) * | 2014-03-04 | 2015-09-11 | Donald Danforth Plant Science Center | New generation of artificial micrornas |
| CN103820442B (zh) * | 2014-03-07 | 2015-10-21 | 中国农业科学院植物保护研究所 | 水稻黑条矮缩病毒RNAi多价靶基因序列及应用 |
| TW201607559A (zh) | 2014-05-12 | 2016-03-01 | 阿尼拉製藥公司 | 治療ｓｅｒｐｉｎｃ１相關疾患之方法和組成物 |
| CN112301031A (zh) | 2014-05-22 | 2021-02-02 | 阿尔尼拉姆医药品有限公司 | 血管紧张素原(AGT)iRNA组合物及其使用方法 |
| IL316808A (en) | 2014-08-20 | 2025-01-01 | Alnylam Pharmaceuticals Inc | Modified double-stranded RNA materials and their uses |
| JOP20200115A1 (ar) | 2014-10-10 | 2017-06-16 | Alnylam Pharmaceuticals Inc | تركيبات وطرق لتثبيط التعبير الجيني عن hao1 (حمض أوكسيداز هيدروكسيلي 1 (أوكسيداز جليكولات)) |
| JOP20200092A1 (ar) | 2014-11-10 | 2017-06-16 | Alnylam Pharmaceuticals Inc | تركيبات iRNA لفيروس الكبد B (HBV) وطرق لاستخدامها |
| AU2015350120B2 (en) | 2014-11-17 | 2021-05-27 | Alnylam Pharmaceuticals, Inc. | Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof |
| EP3234141A4 (en) | 2014-12-18 | 2018-06-20 | Alnylam Pharmaceuticals, Inc. | Reversir tm compounds |
| WO2016104775A1 (ja) | 2014-12-27 | 2016-06-30 | 株式会社ボナック | 遺伝子発現制御のための天然型ｍｉＲＮＡおよびその用途 |
| CA2976445A1 (en) | 2015-02-13 | 2016-08-18 | Alnylam Pharmaceuticals, Inc. | Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof |
| JP6602847B2 (ja) | 2015-03-27 | 2019-11-06 | 株式会社ボナック | デリバリー機能と遺伝子発現制御能を有する一本鎖核酸分子 |
| EP3307316A1 (en) | 2015-06-12 | 2018-04-18 | Alnylam Pharmaceuticals, Inc. | Complement component c5 irna compositions and methods of use thereof |
| WO2017011286A1 (en) | 2015-07-10 | 2017-01-19 | Alnylam Pharmaceuticals, Inc. | Insulin-like growth factor binding protein, acid labile subunit (igfals) and insulin-like growth factor 1 (igf-1) irna compositions and methods of use thereof |
| MX2018002090A (es) | 2015-08-24 | 2018-09-12 | Halo Bio Rnai Therapeutics Inc | Nanoparticulas de polinucleótido para modulación de expresión génica y sus usos. |
| EA201890619A1 (ru) | 2015-09-02 | 2018-09-28 | Элнилэм Фармасьютикалз, Инк. | КОМПОЗИЦИИ iRNA ЛИГАНДА 1 БЕЛКА ЗАПРОГРАММИРОВАННОЙ ГИБЕЛИ КЛЕТОК 1 (PD-L1) И СПОСОБЫ ИХ ПРИМЕНЕНИЯ |
| CN113952353A (zh) * | 2015-11-06 | 2022-01-21 | Ionis制药公司 | 调节载脂蛋白(a)表达 |
| ES3041380T3 (en) | 2015-12-07 | 2025-11-11 | Genzyme Corp | Methods and compositions for treating a serpinc1-associated disorder |
| WO2017214518A1 (en) | 2016-06-10 | 2017-12-14 | Alnylam Pharmaceuticals, Inc. | COMPLETMENT COMPONENT C5 iRNA COMPOSTIONS AND METHODS OF USE THEREOF FOR TREATING PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) |
| TWI788312B (zh) | 2016-11-23 | 2023-01-01 | 美商阿尼拉製藥公司 | 絲胺酸蛋白酶抑制因子Ａ１ ｉＲＮＡ組成物及其使用方法 |
| TWI790217B (zh) | 2016-12-16 | 2023-01-21 | 美商阿尼拉製藥公司 | 使用甲狀腺素運載蛋白（ＴＴＲ）ｉＲＮＡ組成物於治療或預防ＴＴＲ相關疾病之方法 |
| CN108342386B (zh) * | 2017-01-22 | 2022-04-15 | 广州市锐博生物科技有限公司 | 一种多聚寡核酸分子及其在多靶标干扰中的应用 |
| JP2020530442A (ja) | 2017-07-10 | 2020-10-22 | ジェンザイム・コーポレーション | 血友病を有する対象の出血事象を処置するための方法および組成物 |
| AU2018301477A1 (en) | 2017-07-13 | 2020-02-27 | Alnylam Pharmaceuticals Inc. | Lactate dehydrogenase a (LDHA) iRNA compositions and methods of use thereof |
| CN111212649A (zh) * | 2017-07-14 | 2020-05-29 | 光环生物干扰疗法公司 | 用于适体驱动地表面形成自形成多核苷酸纳米颗粒的方法和组合物 |
| EP3710587A1 (en) | 2017-11-16 | 2020-09-23 | Alnylam Pharmaceuticals, Inc. | Kisspeptin 1 (kiss1) irna compositions and methods of use thereof |
| WO2019100039A1 (en) | 2017-11-20 | 2019-05-23 | Alnylam Pharmaceuticals, Inc. | Serum amyloid p component (apcs) irna compositions and methods of use thereof |
| CN111727252A (zh) | 2017-12-18 | 2020-09-29 | 阿尔尼拉姆医药品有限公司 | 高速泳动族盒-1（HMGB1）iRNA组合物及其使用方法 |
| AU2019266207B2 (en) | 2018-05-07 | 2025-04-24 | Alnylam Pharmaceuticals, Inc. | Extrahepatic delivery |
| TWI851574B (zh) | 2018-05-14 | 2024-08-11 | 美商阿尼拉製藥公司 | 血管收縮素原（ＡＧＴ）ｉＲＮＡ組成物及其使用方法 |
| JP7213897B2 (ja) * | 2018-07-20 | 2023-01-27 | グアンジョウ リボビオ カンパニー リミテッド | 核酸ユニットとその高分子核酸及びその応用 |
| CN113227371A (zh) * | 2018-08-27 | 2021-08-06 | 圣诺制药公司 | 微型发夹RNAi触发物(mxRNA)和其使用方法 |
| EP3853364A1 (en) | 2018-09-18 | 2021-07-28 | Alnylam Pharmaceuticals, Inc. | Ketohexokinase (khk) irna compositions and methods of use thereof |
| TW202028465A (zh) | 2018-09-28 | 2020-08-01 | 美商阿尼拉製藥公司 | 甲狀腺素運載蛋白（ＴＴＲ）ｉＲＮＡ組成物及其治療或預防ＴＴＲ相關眼部疾病之使用方法 |
| CN113164507A (zh) * | 2018-09-28 | 2021-07-23 | 圣诺制药公司 | 由多个寡核苷酸构成的通过与靶标的互补相互作用调控基因表达的多靶向核酸构建体 |
| WO2020232430A1 (en) * | 2019-05-16 | 2020-11-19 | University Of South Florida | Methods of downregulating ccl20 genes for treatment of traumatic brain injuries |
| JP2022532652A (ja) | 2019-05-17 | 2022-07-15 | アルニラム ファーマスーティカルズ インコーポレイテッド | オリゴヌクレオチドの経口送達 |
| WO2021022108A2 (en) | 2019-08-01 | 2021-02-04 | Alnylam Pharmaceuticals, Inc. | CARBOXYPEPTIDASE B2 (CPB2) iRNA COMPOSITIONS AND METHODS OF USE THEREOF |
| EP4007812A1 (en) | 2019-08-01 | 2022-06-08 | Alnylam Pharmaceuticals, Inc. | Serpin family f member 2 (serpinf2) irna compositions and methods of use thereof |
| EP4013870A1 (en) | 2019-08-13 | 2022-06-22 | Alnylam Pharmaceuticals, Inc. | Small ribosomal protein subunit 25 (rps25) irna agent compositions and methods of use thereof |
| EP4038189A1 (en) | 2019-10-04 | 2022-08-10 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for silencing ugt1a1 gene expression |
| EP4045652A1 (en) | 2019-10-18 | 2022-08-24 | Alnylam Pharmaceuticals, Inc. | Solute carrier family member irna compositions and methods of use thereof |
| EP4048793A1 (en) | 2019-10-22 | 2022-08-31 | Alnylam Pharmaceuticals, Inc. | Complement component c3 irna compositions and methods of use thereof |
| CA3155921A1 (en) | 2019-11-01 | 2021-05-06 | Alnylam Pharmaceuticals, Inc. | HUNTINGTINE (HTT) TARGETING RNAI AGENT COMPOSITIONS AND METHODS OF USE THEREOF |
| US20230040920A1 (en) | 2019-11-01 | 2023-02-09 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for silencing dnajb1-prkaca fusion gene expression |
| AU2020378414A1 (en) | 2019-11-06 | 2022-05-26 | Alnylam Pharmaceuticals, Inc. | Extrahepatic delivery |
| WO2021092145A1 (en) | 2019-11-06 | 2021-05-14 | Alnylam Pharmaceuticals, Inc. | Transthyretin (ttr) irna composition and methods of use thereof for treating or preventing ttr-associated ocular diseases |
| CN114981431A (zh) | 2019-11-13 | 2022-08-30 | 阿尔尼拉姆医药品有限公司 | 用于治疗血管紧张素原(agt)相关病症的方法和组合物 |
| EP4061945A1 (en) | 2019-11-22 | 2022-09-28 | Alnylam Pharmaceuticals, Inc. | Ataxin3 (atxn3) rnai agent compositions and methods of use thereof |
| BR112022011417A2 (pt) | 2019-12-13 | 2022-08-30 | Alnylam Pharmaceuticals Inc | Composições do agente de irna da fase de leitura aberta 72 do cromossomo humano 9 (c9orf72) e métodos de uso das mesmas |
| TW202138559A (zh) | 2019-12-16 | 2021-10-16 | 美商阿尼拉製藥公司 | 含類ＰＡＴＡＴＩＮ磷脂酶結構域３（ＰＮＰＬＡ３）ｉＲＮＡ組成物及其使用方法 |
| WO2021154941A1 (en) | 2020-01-31 | 2021-08-05 | Alnylam Pharmaceuticals, Inc. | Complement component c5 irna compositions for use in the treatment of amyotrophic lateral sclerosis (als) |
| CA3170377A1 (en) | 2020-02-10 | 2021-08-19 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for silencing vegf-a expression |
| JP7735288B2 (ja) | 2020-02-18 | 2025-09-08 | アルナイラム ファーマシューティカルズ， インコーポレイテッド | アポリポタンパク質Ｃ３（ＡＰＯＣ３）ｉＲＮＡ組成物およびその使用法 |
| EP4114947A1 (en) | 2020-03-05 | 2023-01-11 | Alnylam Pharmaceuticals, Inc. | Complement component c3 irna compositions and methods of use thereof for treating or preventing complement component c3-associated diseases |
| EP4114948A1 (en) | 2020-03-06 | 2023-01-11 | Alnylam Pharmaceuticals, Inc. | Ketohexokinase (khk) irna compositions and methods of use thereof |
| WO2021188611A1 (en) | 2020-03-18 | 2021-09-23 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for treating subjects having a heterozygous alanine-glyoxylate aminotransferase gene (agxt) variant |
| EP4121537A4 (en) * | 2020-03-18 | 2024-07-31 | University Of Massachusetts | OLIGONUCLEOTIDES FOR MAPT MODULATION |
| CA3171757A1 (en) * | 2020-03-18 | 2021-09-23 | Anastasia Khvorova | Oligonucleotides for snca modulation |
| JP2023519274A (ja) | 2020-03-26 | 2023-05-10 | アルナイラム ファーマシューティカルズ， インコーポレイテッド | コロナウイルスｉＲＮＡ組成物およびその使用方法 |
| EP4127171A2 (en) | 2020-03-30 | 2023-02-08 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for silencing dnajc15 gene expression |
| US20230295622A1 (en) | 2020-04-06 | 2023-09-21 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for silencing myoc expression |
| EP4133077A1 (en) | 2020-04-07 | 2023-02-15 | Alnylam Pharmaceuticals, Inc. | Transmembrane serine protease 2 (tmprss2) irna compositions and methods of use thereof |
| WO2021206917A1 (en) | 2020-04-07 | 2021-10-14 | Alnylam Pharmaceuticals, Inc. | ANGIOTENSIN-CONVERTING ENZYME 2 (ACE2) iRNA COMPOSITIONS AND METHODS OF USE THEREOF |
| US20230159933A1 (en) | 2020-04-07 | 2023-05-25 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for silencing scn9a expression |
| EP4143319A1 (en) | 2020-04-27 | 2023-03-08 | Alnylam Pharmaceuticals, Inc. | Apolipoprotein e (apoe) irna agent compositions and methods of use thereof |
| CN116096381A (zh) | 2020-04-30 | 2023-05-09 | 阿尔尼拉姆医药品有限公司 | 补体因子B（CFB）iRNA组合物及其使用方法 |
| US20230183707A1 (en) | 2020-05-21 | 2023-06-15 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting marc1 gene expression |
| CN116075592A (zh) | 2020-06-09 | 2023-05-05 | 阿尔尼拉姆医药品有限公司 | 用于沉默gpam(线粒体甘油-3-磷酸酰基转移酶1)表达的sirna组合物和方法 |
| EP4162050A1 (en) | 2020-06-09 | 2023-04-12 | Alnylam Pharmaceuticals, Inc. | Rnai compositions and methods of use thereof for delivery by inhalation |
| WO2021257782A1 (en) | 2020-06-18 | 2021-12-23 | Alnylam Pharmaceuticals, Inc. | XANTHINE DEHYDROGENASE (XDH) iRNA COMPOSITIONS AND METHODS OF USE THEREOF |
| US20230257745A1 (en) | 2020-07-10 | 2023-08-17 | Alnylam Pharmaceuticals, Inc. | Circular siRNAs |
| EP4217489A1 (en) | 2020-09-24 | 2023-08-02 | Alnylam Pharmaceuticals, Inc. | Dipeptidyl peptidase 4 (dpp4) irna compositions and methods of use thereof |
| WO2022076291A1 (en) | 2020-10-05 | 2022-04-14 | Alnylam Pharmaceuticals, Inc. | G protein-coupled receptor 75 (gpr75) irna compositions and methods of use thereof |
| EP4232581A1 (en) | 2020-10-21 | 2023-08-30 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for treating primary hyperoxaluria |
| EP4232582A1 (en) | 2020-10-23 | 2023-08-30 | Alnylam Pharmaceuticals, Inc. | Mucin 5b (muc5b) irna compositions and methods of use thereof |
| EP4244355A1 (en) | 2020-11-13 | 2023-09-20 | Alnylam Pharmaceuticals, Inc. | Coagulation factor v (f5) irna compositions and methods of use thereof |
| CA3201452A1 (en) | 2020-12-01 | 2022-06-09 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for inhibition of hao1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression |
| CN114606196A (zh) * | 2020-12-04 | 2022-06-10 | 南京大学 | 一种进行siRNA表达和体内递送的细胞疗法 |
| EP4259795A1 (en) | 2020-12-08 | 2023-10-18 | Alnylam Pharmaceuticals, Inc. | Coagulation factor x (f10) irna compositions and methods of use thereof |
| JP2024501857A (ja) | 2020-12-31 | 2024-01-16 | アルナイラム ファーマシューティカルズ， インコーポレイテッド | 環状ジスルフィド修飾リン酸ベースのオリゴヌクレオチドプロドラッグ |
| US20240336914A1 (en) | 2020-12-31 | 2024-10-10 | Alnylam Pharmaceuticals, Inc. | 2'-modified nucleoside based oligonucleotide prodrugs |
| WO2022150260A1 (en) | 2021-01-05 | 2022-07-14 | Alnylam Pharmaceuticals, Inc. | COMPLEMENT COMPONENT 9 (C9) iRNA COMPOSITIONS AND METHODS OF USE THEREOF |
| WO2022166849A1 (en) * | 2021-02-08 | 2022-08-11 | Ractigen Therapeutics | Multi-valent oligonucleotide agent and methods of use thereof |
| WO2022174000A2 (en) | 2021-02-12 | 2022-08-18 | Alnylam Pharmaceuticals, Inc. | Superoxide dismutase 1 (sod1) irna compositions and methods of use thereof for treating or preventing superoxide dismutase 1- (sod1-) associated neurodegenerative diseases |
| CN117222739A (zh) | 2021-02-25 | 2023-12-12 | 阿尔尼拉姆医药品有限公司 | 朊病毒蛋白(prnp)irna组合物和其使用方法 |
| AU2022226098A1 (en) | 2021-02-26 | 2023-08-24 | Alnylam Pharmaceuticals, Inc. | KETOHEXOKINASE (KHK) iRNA COMPOSITIONS AND METHODS OF USE THEREOF |
| JP2024508896A (ja) | 2021-03-04 | 2024-02-28 | アルナイラム ファーマシューティカルズ， インコーポレイテッド | アンジオポエチン様３（ＡＮＧＰＴＬ３）ｉＲＮＡ組成物およびその使用方法 |
| EP4305169A1 (en) | 2021-03-12 | 2024-01-17 | Alnylam Pharmaceuticals, Inc. | Glycogen synthase kinase 3 alpha (gsk3a) irna compositions and methods of use thereof |
| TW202305134A (zh) | 2021-03-29 | 2023-02-01 | 美商艾拉倫製藥股份有限公司 | 杭丁頓蛋白（ＨＴＴ）ｉＲＮＡ劑組成物及其使用方法 |
| EP4314293A1 (en) | 2021-04-01 | 2024-02-07 | Alnylam Pharmaceuticals, Inc. | Proline dehydrogenase 2 (prodh2) irna compositions and methods of use thereof |
| IL307926A (en) | 2021-04-26 | 2023-12-01 | Alnylam Pharmaceuticals Inc | Transmembrane assemblies, serine 6 ((TMPRSS6 IRNA) and methods of using them |
| EP4330396A1 (en) | 2021-04-29 | 2024-03-06 | Alnylam Pharmaceuticals, Inc. | Signal transducer and activator of transcription factor 6 (stat6) irna compositions and methods of use thereof |
| JP2024522068A (ja) | 2021-05-18 | 2024-06-11 | アルナイラム ファーマシューティカルズ， インコーポレイテッド | ナトリウム－グルコース共輸送体２（ｓｇｌｔ２）ｉｒｎａ組成物およびその使用方法 |
| WO2022256395A1 (en) | 2021-06-02 | 2022-12-08 | Alnylam Pharmaceuticals, Inc. | Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof |
| TW202308663A (zh) | 2021-06-04 | 2023-03-01 | 美商艾拉倫製藥股份有限公司 | 人類染色體９開讀框７２（Ｃ９ＯＲＦ７２）ｉＲＮＡ劑組成物及其使用方法 |
| AR126070A1 (es) | 2021-06-08 | 2023-09-06 | Alnylam Pharmaceuticals Inc | Composiciones y métodos para tratar o prevenir la enfermedad de stargardt y/o trastornos asociados con la proteína transportadora de retinol 4 (rbp4) |
| WO2022271624A1 (en) * | 2021-06-21 | 2022-12-29 | The University Of North Carolina At Chapel Hill | Inverted chimeric sirna molecules and methods of use thereof |
| MX2023015489A (es) | 2021-06-30 | 2024-01-19 | Alnylam Pharmaceuticals Inc | Metodos y composiciones para tratar un trastorno asociado al angiotensinogeno (agt). |
| US20250270562A1 (en) | 2021-07-09 | 2025-08-28 | Alnylam Pharmaceuticals, Inc. | Bis-rnai compounds for cns delivery |
| EP4373934A1 (en) | 2021-07-19 | 2024-05-29 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for treating subjects having or at risk of developing a non-primary hyperoxaluria disease or disorder |
| KR20240036041A (ko) | 2021-07-21 | 2024-03-19 | 알닐람 파마슈티칼스 인코포레이티드 | 대사 장애-연관 표적 유전자 iRNA 조성물 및 이의 사용 방법 |
| TW202325312A (zh) | 2021-07-23 | 2023-07-01 | 美商艾拉倫製藥股份有限公司 | β－鏈蛋白（ＣＴＮＮＢ１）ｉＲＮＡ組成物及其使用方法 |
| EP4377458A1 (en) | 2021-07-29 | 2024-06-05 | Alnylam Pharmaceuticals, Inc. | 3-hydroxy-3-methylglutaryl-coa reductase (hmgcr) irna compositions and methods of use thereof |
| CA3227852A1 (en) | 2021-08-03 | 2023-02-09 | Alnylam Pharmaceuticals, Inc. | Transthyretin (ttr) irna compositions and methods of use thereof |
| IL310295A (en) | 2021-08-04 | 2024-03-01 | Alnylam Pharmaceuticals Inc | iRNA compositions and methods for silencing angiotensinogen (AGT) |
| JP2024534766A (ja) | 2021-08-13 | 2024-09-26 | アルナイラム ファーマシューティカルズ， インコーポレイテッド | 第ＸＩＩ因子（Ｆ１２）ｉＲＮＡ組成物およびその使用方法 |
| EP4395790A2 (en) | 2021-08-31 | 2024-07-10 | Alnylam Pharmaceuticals, Inc. | Cell death-inducing dffa-like effector b (cideb) irna compositions and methods of use thereof |
| EP4402263A2 (en) * | 2021-09-14 | 2024-07-24 | Argonaute Rna Limited | Treatment of cardiovascular disease |
| EP4401742A2 (en) | 2021-09-17 | 2024-07-24 | Alnylam Pharmaceuticals, Inc. | Irna compositions and methods for silencing complement component 3 (c3) |
| CN118159654A (zh) | 2021-09-20 | 2024-06-07 | 阿尔尼拉姆医药品有限公司 | 抑制素亚基βE（INHBE）调节剂组合物及其使用方法 |
| CN118369427A (zh) | 2021-10-15 | 2024-07-19 | 阿尔尼拉姆医药品有限公司 | 肝外递送irna组合物及其使用方法 |
| KR20240090727A (ko) | 2021-10-22 | 2024-06-21 | 세일 바이오메디슨스, 인크. | Mrna 백신 조성물 |
| CA3234636A1 (en) | 2021-10-29 | 2023-05-04 | Alnylam Pharmaceuticals, Inc. | Complement factor b (cfb) irna compositions and methods of use thereof |
| EP4423272A2 (en) | 2021-10-29 | 2024-09-04 | Alnylam Pharmaceuticals, Inc. | Huntingtin (htt) irna agent compositions and methods of use thereof |
| EP4436588A1 (en) | 2021-11-23 | 2024-10-02 | Sail Biomedicines, Inc. | A bacteria-derived lipid composition and use thereof |
| JP2025500373A (ja) | 2021-12-20 | 2025-01-09 | セイル バイオメディシンズ インコーポレイテッド | Ｍｒｎａ治療用組成物 |
| WO2023141314A2 (en) | 2022-01-24 | 2023-07-27 | Alnylam Pharmaceuticals, Inc. | Heparin sulfate biosynthesis pathway enzyme irna agent compositions and methods of use thereof |
| EP4547683A2 (en) | 2022-06-30 | 2025-05-07 | Alnylam Pharmaceuticals, Inc. | Cyclic-disulfide modified phosphate based oligonucleotide prodrugs |
| MA71735A (fr) | 2022-09-15 | 2025-05-30 | Regeneron Pharmaceuticals, Inc. | Compositions d'arni de 17b-hydroxystéroïde déshydrogénase de type 13 (hsd17b13) et leurs procédés d'utilisation |
| EP4594492A1 (en) | 2022-09-30 | 2025-08-06 | Alnylam Pharmaceuticals, Inc. | Modified double-stranded rna agents |
| CN120359023A (zh) | 2022-11-10 | 2025-07-22 | 赛欧生物医药股份有限公司 | 包含脂质纳米颗粒或脂质重构的天然信使包的rna组合物 |
| EP4654952A1 (en) | 2023-01-27 | 2025-12-03 | Sail Biomedicines, Inc. | A modified lipid composition and uses thereof |
| WO2024216155A1 (en) | 2023-04-12 | 2024-10-17 | Alnylam Pharmaceuticals, Inc. | Extrahepatic delivery of double-stranded rna agents |
| WO2024220752A2 (en) | 2023-04-19 | 2024-10-24 | Sail Biomedicines, Inc. | Rna therapeutic compositions |
| WO2024220712A2 (en) | 2023-04-19 | 2024-10-24 | Sail Biomedicines, Inc. | Vaccine compositions |
| WO2024220625A1 (en) | 2023-04-19 | 2024-10-24 | Sail Biomedicines, Inc. | Delivery of polynucleotides from lipid nanoparticles comprising rna and ionizable lipids |
| WO2024228030A2 (en) | 2023-05-04 | 2024-11-07 | Argonaute RNA Limited | Dual silencing |
| WO2025034422A1 (en) | 2023-08-04 | 2025-02-13 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for treating ctnnb1-associated disorders |
| WO2025064660A2 (en) | 2023-09-21 | 2025-03-27 | Alnylam Pharmaceuticals, Inc. | Activin a receptor type 1c (acvr1c) irna compositions and methods of use thereof |
| WO2025076031A2 (en) | 2023-10-03 | 2025-04-10 | Alnylam Pharmaceuticals, Inc. | Peritoneal macrophages comprising a nanoparticle encapsulating a nucleic acid molecule and methods of use thereof |
Family Cites Families (124)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2528107B2 (ja) | 1985-03-15 | 1996-08-28 | サマ−トン，ジエ−ムス | ポリヌクレオチド測定試薬と方法 |
| US5217866A (en) | 1985-03-15 | 1993-06-08 | Anti-Gene Development Group | Polynucleotide assay reagent and method |
| US5034506A (en) | 1985-03-15 | 1991-07-23 | Anti-Gene Development Group | Uncharged morpholino-based polymers having achiral intersubunit linkages |
| US5166315A (en) | 1989-12-20 | 1992-11-24 | Anti-Gene Development Group | Sequence-specific binding polymers for duplex nucleic acids |
| US5506337A (en) | 1985-03-15 | 1996-04-09 | Antivirals Inc. | Morpholino-subunit combinatorial library and method |
| US5521063A (en) | 1985-03-15 | 1996-05-28 | Antivirals Inc. | Polynucleotide reagent containing chiral subunits and methods of use |
| US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
| US5714331A (en) | 1991-05-24 | 1998-02-03 | Buchardt, Deceased; Ole | Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility |
| US5539082A (en) | 1993-04-26 | 1996-07-23 | Nielsen; Peter E. | Peptide nucleic acids |
| US5719262A (en) | 1993-11-22 | 1998-02-17 | Buchardt, Deceased; Ole | Peptide nucleic acids having amino acid side chains |
| US5814618A (en) | 1993-06-14 | 1998-09-29 | Basf Aktiengesellschaft | Methods for regulating gene expression |
| WO1994029442A2 (en) | 1993-06-14 | 1994-12-22 | Basf Aktiengesellschaft | Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters |
| US5856174A (en) | 1995-06-29 | 1999-01-05 | Affymetrix, Inc. | Integrated nucleic acid diagnostic device |
| US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
| US5898031A (en) | 1996-06-06 | 1999-04-27 | Isis Pharmaceuticals, Inc. | Oligoribonucleotides for cleaving RNA |
| US20040171031A1 (en) | 1996-06-06 | 2004-09-02 | Baker Brenda F. | Sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation |
| US5874554A (en) | 1996-12-13 | 1999-02-23 | Incyte Pharmaceuticals, Inc. | Methods and solvent vehicles for reagent delivery in oligonucleotide synthesis using automated pulse jetting devices |
| US6794499B2 (en) | 1997-09-12 | 2004-09-21 | Exiqon A/S | Oligonucleotide analogues |
| US7572582B2 (en) | 1997-09-12 | 2009-08-11 | Exiqon A/S | Oligonucleotide analogues |
| US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| US6218181B1 (en) | 1998-03-18 | 2001-04-17 | The Salk Institute For Biological Studies | Retroviral packaging cell line |
| WO2000043507A1 (en) | 1999-01-19 | 2000-07-27 | Unilever Plc | Method for producing antibody fragments |
| DE19956568A1 (de) | 1999-01-30 | 2000-08-17 | Roland Kreutzer | Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens |
| US7084125B2 (en) | 1999-03-18 | 2006-08-01 | Exiqon A/S | Xylo-LNA analogues |
| AU776362B2 (en) | 1999-05-04 | 2004-09-09 | Roche Innovation Center Copenhagen A/S | L-ribo-LNA analogues |
| GB9927444D0 (en) | 1999-11-19 | 2000-01-19 | Cancer Res Campaign Tech | Inhibiting gene expression |
| DE10100586C1 (de) | 2001-01-09 | 2002-04-11 | Ribopharma Ag | Verfahren zur Hemmung der Expression eines Ziegens |
| KR20080023768A (ko) | 2000-03-30 | 2008-03-14 | 화이트헤드 인스티튜트 포 바이오메디칼 리서치 | Ｒｎａ 간섭의 ｒｎａ 서열 특이적인 매개체 |
| KR100909681B1 (ko) | 2000-12-01 | 2009-07-29 | 막스-플랑크-게젤샤프트 츄어 푀르더룽 데어 비쎈샤프텐 에.파우. | Ｒｎａ 간섭을 매개하는 작은 ｒｎａ 분자 |
| US7767802B2 (en) | 2001-01-09 | 2010-08-03 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of anti-apoptotic genes |
| US7423142B2 (en) | 2001-01-09 | 2008-09-09 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of anti-apoptotic genes |
| US20070270579A1 (en) | 2001-05-18 | 2007-11-22 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA) |
| US20070173473A1 (en) * | 2001-05-18 | 2007-07-26 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of proprotein convertase subtilisin Kexin 9 (PCSK9) gene expression using short interfering nucleic acid (siNA) |
| US20050196781A1 (en) * | 2001-05-18 | 2005-09-08 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of STAT3 gene expression using short interfering nucleic acid (siNA) |
| US20050191618A1 (en) * | 2001-05-18 | 2005-09-01 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of human immunodeficiency virus (HIV) gene expression using short interfering nucleic acid (siNA) |
| US10590418B2 (en) | 2001-07-23 | 2020-03-17 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for RNAi mediated inhibition of gene expression in mammals |
| CA2936534C (en) | 2001-07-23 | 2021-01-26 | The Board Of Trustees Of Leland Stanford Junior University | Methods and compositions for rnai mediated inhibition of gene expression in mammals |
| AU2002334307A1 (en) | 2001-09-04 | 2003-03-18 | Exiqon A/S | Novel lna compositions and uses thereof |
| DE10163098B4 (de) | 2001-10-12 | 2005-06-02 | Alnylam Europe Ag | Verfahren zur Hemmung der Replikation von Viren |
| US7745418B2 (en) | 2001-10-12 | 2010-06-29 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting viral replication |
| DE10202419A1 (de) | 2002-01-22 | 2003-08-07 | Ribopharma Ag | Verfahren zur Hemmung der Expression eines durch eine Chromosomen-Aberration entstandenen Zielgens |
| KR100464261B1 (ko) | 2002-01-24 | 2005-01-03 | 주식회사 파나진 | Ｐｎａ 올리고머를 합성하기 위한 신규한 단량체 및 그의제조방법 |
| US20100240730A1 (en) | 2002-02-20 | 2010-09-23 | Merck Sharp And Dohme Corp. | RNA Interference Mediated Inhibition of Gene Expression Using Chemically Modified Short Interfering Nucleic Acid (siNA) |
| KR20030084444A (ko) | 2002-04-26 | 2003-11-01 | 주식회사 파나진 | Ｐｎａ 올리고머를 합성하기 위한 신규한 단량체 및 그의제조방법 |
| US7569575B2 (en) | 2002-05-08 | 2009-08-04 | Santaris Pharma A/S | Synthesis of locked nucleic acid derivatives |
| AU2003282722A1 (en) | 2002-10-02 | 2004-04-23 | Alnylam Pharmaceuticals Inc. | Therapeutic compositions |
| WO2004035765A2 (en) | 2002-10-18 | 2004-04-29 | Nucleonics, Inc. | Double-stranded rna structures and constructs, and methods for generating and using the same |
| US20080188429A1 (en) * | 2002-12-27 | 2008-08-07 | Iyer Radhakrishnan P | Synthetic siRNA compounds and methods for the downregulation of gene expression |
| JP2004261002A (ja) | 2003-01-08 | 2004-09-24 | Tsutomu Suzuki | ｓｉＲＮＡの製造方法 |
| WO2004064737A2 (en) | 2003-01-17 | 2004-08-05 | Alnylam Pharmaceuticals | Therapeutics compositions |
| EP2239329A1 (en) | 2003-03-07 | 2010-10-13 | Alnylam Pharmaceuticals, Inc. | Therapeutic compositions |
| US20050233342A1 (en) | 2003-03-07 | 2005-10-20 | Muthiah Manoharan | Methods of preventing off-target gene silencing |
| AU2004227414A1 (en) | 2003-04-03 | 2004-10-21 | Alnylam Pharmaceuticals | iRNA conjugates |
| CA2521464C (en) | 2003-04-09 | 2013-02-05 | Alnylam Pharmaceuticals, Inc. | Irna conjugates |
| US20070179100A1 (en) | 2003-04-09 | 2007-08-02 | Muthiah Manoharan | Protected monomers |
| WO2004091572A2 (en) * | 2003-04-09 | 2004-10-28 | Biodelivery Sciences International, Inc. | Cochleate compositions directed against expression of proteins |
| CA2522349A1 (en) | 2003-04-17 | 2004-11-04 | Alnylam Pharmaceuticals, Inc. | Protected monomers |
| CA2522637C (en) | 2003-04-17 | 2014-01-21 | Alnylam Pharmaceuticals, Inc. | Modified irna agents |
| WO2004104199A2 (en) * | 2003-05-15 | 2004-12-02 | Oligo Engine, Inc. | Modulation of gene expression using dna-dna hybrids |
| CA2542232A1 (en) | 2003-06-09 | 2005-01-20 | Alnylam Pharmaceuticals, Inc. | Method for treating neurodegenerative disease by inhibiting alpha-synuclein |
| US7595306B2 (en) | 2003-06-09 | 2009-09-29 | Alnylam Pharmaceuticals Inc | Method of treating neurodegenerative disease |
| US7786290B2 (en) | 2003-06-13 | 2010-08-31 | Alnylam Pharmaceuticals, Inc. | Double-stranded ribonucleic acid with increased effectiveness in an organism |
| US7211668B2 (en) | 2003-07-28 | 2007-05-01 | Panagene, Inc. | PNA monomer and precursor |
| CA2539256C (en) * | 2003-09-17 | 2012-04-24 | Let There Be Hope Medical Research Institute | Targeted lipid-drug formulations for delivery of drugs to myeloid and lymphoid immune cells |
| AU2005222902B2 (en) | 2004-03-12 | 2010-06-10 | Alnylam Pharmaceuticals, Inc. | iRNA agents targeting VEGF |
| CA2561741C (en) | 2004-04-05 | 2016-09-27 | Alnylam Pharmaceuticals, Inc. | Processes and reagents for oligonucleotide synthesis and purification |
| US7626014B2 (en) | 2004-04-27 | 2009-12-01 | Alnylam Pharmaceuticals | Single-stranded and double-stranded oligonucleotides comprising a 2-arylpropyl moiety |
| AU2005323437B2 (en) | 2004-04-30 | 2011-10-06 | Alnylam Pharmaceuticals, Inc. | Oligonucleotides comprising a C5-modified pyrimidine |
| EP1765847A4 (en) | 2004-05-27 | 2010-10-20 | Alnylam Pharmaceuticals Inc | NUCLEASERESISTENT DOUBLE-STRANDED RIBONUCLEIC ACID |
| CA2572151A1 (en) | 2004-06-30 | 2006-08-24 | Alnylam Pharmaceuticals, Inc. | Oligonucleotides comprising a non-phosphate backbone linkage |
| WO2006093526A2 (en) | 2004-07-21 | 2006-09-08 | Alnylam Pharmaceuticals, Inc. | Oligonucleotides comprising a modified or non-natural nucleobase |
| US20080213891A1 (en) | 2004-07-21 | 2008-09-04 | Alnylam Pharmaceuticals, Inc. | RNAi Agents Comprising Universal Nucleobases |
| US7632932B2 (en) | 2004-08-04 | 2009-12-15 | Alnylam Pharmaceuticals, Inc. | Oligonucleotides comprising a ligand tethered to a modified or non-natural nucleobase |
| WO2006020768A2 (en) | 2004-08-10 | 2006-02-23 | Alnylam Pharmaceuticals, Inc. | Chemically modified oligonucleotides |
| WO2006036916A2 (en) | 2004-09-24 | 2006-04-06 | Alnylam Pharmaceuticals, Inc. | Rnai modulation of apob and uses thereof |
| US20060287264A1 (en) | 2004-11-24 | 2006-12-21 | Philipp Hadwiger | RNAi modulation of the BCR-ABL fusion gene and uses thereof |
| CA2589406A1 (en) | 2004-12-09 | 2006-06-15 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inducing an immune response in a mammal and methods of avoiding an immune response to oligonucleotide agents such as short interfering rnas |
| CA2590768A1 (en) | 2004-12-14 | 2006-06-22 | Alnylam Pharmaceuticals, Inc. | Rnai modulation of mll-af4 and uses thereof |
| EP3372676A1 (en) | 2004-12-21 | 2018-09-12 | Monsanto Technology, LLC | Recombinant dna constructs and methods for controlling gene expression |
| ATE457363T1 (de) * | 2004-12-29 | 2010-02-15 | Applied Biosystems Llc | Verfahren, zusammensetzungen und kits zur bildung einander ergänzender polynukleotide |
| US20090005332A1 (en) * | 2004-12-30 | 2009-01-01 | Hauser Todd M | Compositions and Methods for Modulating Gene Expression Using Self-Protected Oligonucleotides |
| EP1833490A4 (en) | 2005-01-07 | 2010-09-15 | Alnylam Pharmaceuticals Inc | INTERFERING RNA MODULATION OF SYNCYTIAL RESPIRATORY VIRUS AND THERAPEUTIC USES THEREOF |
| AU2006209192A1 (en) | 2005-01-24 | 2006-08-03 | Alnylam Pharmaceuticals, Inc. | RNAi modulation of the Nogo-L or Nogo-R gene and uses thereof |
| US7718625B2 (en) * | 2005-01-27 | 2010-05-18 | University Of South Florida | Polynucleotides targeted against the extended 5′-UTR region of argininosuccinate synthase and uses thereof |
| AU2006210443B2 (en) * | 2005-02-03 | 2011-01-27 | Benitec, Inc. | RNAi expression constructs |
| CA2608964A1 (en) | 2005-06-27 | 2007-01-04 | Alnylam Pharmaceuticals, Inc. | Rnai modulation of hif-1 and therapeutic uses thereof |
| JP2009502138A (ja) | 2005-07-21 | 2009-01-29 | アルナイラム ファーマシューティカルズ インコーポレイテッド | ＲｈｏＡ遺伝子のＲＮＡｉ調節及びその使用法 |
| EP1917357A2 (en) * | 2005-08-01 | 2008-05-07 | Purdue Research Foundation | Multivalent rna nanoparticles for delivery of active agents to a cell |
| WO2007021896A2 (en) | 2005-08-10 | 2007-02-22 | Alnylam Pharmaceuticals, Inc. | Chemically modified oligonucleotides for use in modulating micro rna and uses thereof |
| US20070213292A1 (en) | 2005-08-10 | 2007-09-13 | The Rockefeller University | Chemically modified oligonucleotides for use in modulating micro RNA and uses thereof |
| US20070148246A1 (en) * | 2005-08-11 | 2007-06-28 | Dan Luo | Nucleic Acid-Based Matrixes |
| CA2619534A1 (en) | 2005-08-18 | 2007-02-22 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for treating neurological disease |
| EP2325315B1 (en) | 2005-10-28 | 2014-05-07 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of huntingtin gene |
| CA2627585A1 (en) | 2005-11-01 | 2007-05-10 | Alnylam Pharmaceuticals, Inc. | Rnai inhibition of influenza virus replication |
| JP4929288B2 (ja) | 2005-11-04 | 2012-05-09 | アルナイラム ファーマシューティカルズ， インコーポレイテッド | Ｎａｖ１．８遺伝子の発現を抑制するための組成物および方法 |
| EP2363134B1 (en) | 2005-11-09 | 2014-01-08 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of factor V Leiden mutant gene |
| CA2527144C (en) | 2005-11-15 | 2014-04-29 | Queen's University At Kingston | Reversibly switchable surfactants and methods of use thereof |
| WO2007059760A1 (de) * | 2005-11-25 | 2007-05-31 | Mologen Ag | Dna-konstrukte zur spezifischen hemmung der genexpression durch rna-interferenz |
| WO2007091269A2 (en) | 2006-02-08 | 2007-08-16 | Quark Pharmaceuticals, Inc. | NOVEL TANDEM siRNAS |
| WO2007109097A2 (en) | 2006-03-16 | 2007-09-27 | Alnylam Pharmaceuticals, Inc. | RNAi MODULATION OF TGF-BETA AND THERAPEUTIC USES THEREOF |
| KR101362681B1 (ko) | 2006-03-31 | 2014-02-13 | 알닐람 파마슈티칼스 인코포레이티드 | Ｅｇ5 유전자의 발현을 억제하는 조성물 및 억제 방법 |
| EP2013222B1 (en) | 2006-04-28 | 2013-02-13 | Alnylam Pharmaceuticals Inc. | Compositions and methods for inhibiting expression of a gene from the jc virus |
| SI2735568T1 (en) | 2006-05-10 | 2018-01-31 | Sarepta Therapeutics, Inc. | Analogues of the oligonucleotide, with cationic links between subunits |
| CN103614375A (zh) | 2006-05-11 | 2014-03-05 | 阿尔尼拉姆医药品有限公司 | 抑制pcsk9基因表达的组合物和方法 |
| CN101506358B (zh) * | 2006-05-15 | 2013-07-17 | 免疫医学股份有限公司 | 使用偶合的抗体或抗体片段治疗人免疫缺陷病毒感染的方法和组合物 |
| BRPI0712034A2 (pt) | 2006-05-19 | 2012-01-10 | Alnylam Pharmaceuticals Inc | modulação de rnai de aha e usos terapêuticos do mesmo |
| JP2009537179A (ja) | 2006-05-19 | 2009-10-29 | ザ スクリップス リサーチ インスティテュート | 蛋白質ミスフォールディングの処置 |
| WO2007137220A2 (en) | 2006-05-22 | 2007-11-29 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of ikk-b gene |
| WO2008008719A2 (en) | 2006-07-10 | 2008-01-17 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of the myc gene |
| US20080039415A1 (en) | 2006-08-11 | 2008-02-14 | Gregory Robert Stewart | Retrograde transport of sirna and therapeutic uses to treat neurologic disorders |
| US7737266B2 (en) | 2006-09-18 | 2010-06-15 | Board Of Regents, The University Of Texas System | RNAi modulation of SCAP and therapeutics uses thereof |
| WO2008036929A2 (en) | 2006-09-21 | 2008-03-27 | Alnylam Pharmaceuticals, Inc. | Complex for transferring an anionic substance into a cell |
| WO2008036933A2 (en) | 2006-09-21 | 2008-03-27 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of the hamp gene |
| WO2008042973A2 (en) | 2006-10-03 | 2008-04-10 | Alnylam Pharmaceuticals, Inc. | Lipid containing formulations |
| US8034921B2 (en) | 2006-11-21 | 2011-10-11 | Alnylam Pharmaceuticals, Inc. | IRNA agents targeting CCR5 expressing cells and uses thereof |
| CA2682161A1 (en) | 2007-03-29 | 2008-10-09 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of a gene from ebola virus |
| US8877917B2 (en) | 2007-04-23 | 2014-11-04 | Alnylam Pharmaceuticals, Inc. | Glycoconjugates of RNA interference agents |
| US20110250138A1 (en) | 2007-08-01 | 2011-10-13 | Alnylam Pharmaceuticals, Inc. | Single-stranded and double-stranded oligonucleotides comprising a metal-chelating ligand |
| CA2704261C (en) | 2007-11-15 | 2015-05-26 | Avi Biopharma, Inc. | Method of synthesis of morpholino oligomers |
| WO2009082607A2 (en) | 2007-12-04 | 2009-07-02 | Alnylam Pharmaceuticals, Inc. | Targeting lipids |
| WO2010078516A2 (en) * | 2009-01-01 | 2010-07-08 | Cornell University | Multifunctional nucleic acid nano-structures |
| US20120016007A1 (en) | 2009-02-04 | 2012-01-19 | Dong Ki Lee | Small interference rna complex with increased intracellular transmission capacity |
| US8841438B2 (en) | 2009-05-22 | 2014-09-23 | The Research Foundation Of The University Of New York | Trans-acting RNA switches |
| CA2764158A1 (en) | 2009-06-01 | 2010-12-09 | Halo-Bio Rnai Therapeutics, Inc. | Polynucleotides for multivalent rna interference, compositions and methods of use thereof |
-
2010
- 2010-06-01 CA CA2764158A patent/CA2764158A1/en not_active Abandoned
- 2010-06-01 CN CN201080034204.7A patent/CN102575252B/zh active Active
- 2010-06-01 US US13/375,460 patent/US9200276B2/en active Active
- 2010-06-01 WO PCT/US2010/036962 patent/WO2010141511A2/en not_active Ceased
- 2010-06-01 JP JP2012513363A patent/JP5875976B2/ja not_active Expired - Fee Related
- 2010-06-01 ES ES10783959T patent/ES2804764T3/es active Active
- 2010-06-01 EP EP10783959.9A patent/EP2438168B1/en active Active
-
2015
- 2015-07-31 JP JP2015151507A patent/JP2015192674A/ja active Pending
- 2015-11-30 US US14/954,653 patent/US9957505B2/en not_active Expired - Fee Related
-
2018
- 2018-04-30 US US15/967,052 patent/US20180346908A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2010141511A3 (en) | 2011-04-21 |
| CN102575252A (zh) | 2012-07-11 |
| EP2438168A4 (en) | 2014-01-22 |
| EP2438168A2 (en) | 2012-04-11 |
| WO2010141511A2 (en) | 2010-12-09 |
| US20120184598A1 (en) | 2012-07-19 |
| JP5875976B2 (ja) | 2016-03-02 |
| CN102575252B (zh) | 2016-04-20 |
| US20180346908A1 (en) | 2018-12-06 |
| JP2012528572A (ja) | 2012-11-15 |
| US20160160215A1 (en) | 2016-06-09 |
| US9200276B2 (en) | 2015-12-01 |
| ES2804764T3 (es) | 2021-02-09 |
| EP2438168B1 (en) | 2020-02-12 |
| JP2015192674A (ja) | 2015-11-05 |
| US9957505B2 (en) | 2018-05-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9957505B2 (en) | Polynucleotides for multivalent RNA interference, compositions and methods of use thereof | |
| US20110159586A1 (en) | Compositions and methods for modulating gene expression using asymmetrically-active precursor polynucleotides | |
| US8513401B2 (en) | Double stranded nucleic acid targeting low copy promoter-specific RNA | |
| CN107406852B (zh) | 用于莱伯氏先天性黑蒙的寡核苷酸疗法 | |
| US9953131B2 (en) | Multi-targeting short interfering RNAs | |
| WO2005056750A2 (en) | Inversion-duplication of nucleic acids and libraries prepared thereby | |
| KR20220123398A (ko) | 합성 가이드 rna, 이의 조성물, 방법 및 용도 | |
| WO2009046104A1 (en) | Aptamer-targeted sirna to prevent attenuation or suppression of t cell function | |
| US20190300882A1 (en) | Methods of treating neuroblastoma and reagents therefor | |
| WO2006074108A2 (en) | Compositions and methods for modulating gene expression using self-protected oligonucleotides | |
| US20220298507A1 (en) | Compositions and methods for rna interference | |
| WO2004024863A2 (en) | Adenoviral va1 pol iii expression system for rna expression | |
| WO2018018077A1 (en) | Methods of treating breast cancer and reagents therefor | |
| JP4536112B2 (ja) | ＲＮＡｉ耐性ウイルス株を克服する新手法 | |
| EP2502997A1 (en) | MicroRNA inhibiting nucleic acid molecule | |
| JP2022531580A (ja) | ベクターでの使用のためのマルチプレックス化ｓｈＲＮＡ | |
| US20060287269A1 (en) | Short interfering nucleic acid hybrids and methods thereof | |
| WO2021219708A1 (en) | Sina molecules, methods of production and uses thereof | |
| Grimpe | Aspects of antisense oligodeoxynucleotide, ribozyme, DNA enzyme and RNAi design | |
| Feřtek | Side-effects of siRNA-induced gene silencing |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20150601 |
|
| FZDE | Dead |
Effective date: 20200831 |